Discovery Laboratories Inc. announced unaudited consolidated earnings results for the first quarter ended March 31, 2013. For the quarter, operating loss was $12,620,000 against $6,580,000 for the same period a year ago. The increase in operating loss from 2012 to 2013 is primarily due to (i) expenses of $2.7 million in the first quarter of 2013 related to the company's U.S. specialty respiratory critical care commercial and medical affairs organizations that are experienced in neonatal/pediatric respiratory critical care and are focused on gaining hospital formulary acceptance of SURFAXIN and adoption of AFECTAIR; (ii) $1.6 million of expenses in the first quarter of 2013 to advance the AEROSURF development program, primarily the optimization of the CAG and the technology transfer of the lyophilized KL4 surfactant manufacturing process to a CMO; and, (iii) a $1.3 million increase in raw material purchases for drug product manufacturing in support of the SURFAXIN and AEROSURF programs. Net loss was $12,635,000 against $10,016,000 for the same period a year ago. Net loss per common share was $0.29 against $0.37 for the same period a year ago. Operating cash outflows before financing activities were $10.4 million. For the second quarter of 2013, the company anticipates operating cash outflows of approximately $10.0 million, before taking into account financing activities.

Discovery Laboratories Inc. proposed to amend amended and restated certificate of incorporation to increase the number of authorized shares of common stock available for issuance from 100 million to 150 million at the AGM to be held on June 11, 2013.

Discovery Laboratories Inc. filed its 10-K on Mar 15, 2013 for the period ending Dec 31, 2012. In this report its auditor, Ernst & Young LLP, gave an unqualified opinion expressing doubt that the company can continue as a going concern.